跳至主要内容
临床试验/NCT00855400
NCT00855400已完成1 期

Phase I/II Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2007年2月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
11
试验地点
2
主要终点
Forced vital capacity

研究概览

简要总结

The purpose of this clinical trial is to asses the feasibility and the security of the intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sclerosis patients.

详细描述

Patients with Amyotrophic Lateral Sclerosis (ALS) typically endure a progressive paralysis due to the continued loss of motoneurons that leads them to death in less than 5 years. No treatment has changed its natural history. Intraspinal injections of bone marrow mononuclear cells (MNC) have been able to ameliorate the course of ALS in murine models, acting as pumps of trophic factors that keep the motoneurons functional. We have designed a phase I/II clinical trial to check the feasibility of this approach in humans.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnose established following the World Federation of Neurology criteria
  • More than 6 and less than 36 months of evolution of the disease
  • Medullar onset of the disease
  • More than 20 and less than 65 years old
  • Forced Vital Capacity equal or superior to 50%
  • Total time of oxygen saturation <90% inferior to 2% of the sleeping time
  • Signed informed consent

排除标准

  • Neurological or psychiatric concomitant disease
  • Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy or nasogastric tube
  • Concomitant systemic disease
  • Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last 12 months
  • Inclusion in other clinical trials
  • Unability to understand the informed consent

结局指标

主要结局

Forced vital capacity

时间窗: Every 3 months

次要结局

  • ALS-FRS, MRC and Norris scales(Every 3 months)
  • Absence of adverse events(Every week / month depending on the study phase)

研究者

发起方
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
申办方类型
Other

研究点 (2)

Loading locations...

相似试验